Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity

Oct 20 2016

• By Jessica Merrill

Listen to this article

New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.

Anti-recessionary injection (vaccination) by hundred dollar denomination close up on a black background

New drugs for atopic dermatitis – a chronic rash that falls under the eczema umbrella but can be severe – are poised to launch in 2017 and establish the therapy area as a multi-billion drug category. These include Regeneron Pharmaceuticals Inc./Sanofi’s Dupixent (duplimumab), the first biologic to treat the disease systemically, and Pfizer Inc.’s crisaborole, a novel topical non-steroidal anti-inflammatory.

The therapy area is expected to become a blockbuster-sized drug market because of high demand for effective treatments in a...

More from Dermatological

Galderma Gets First Biologic To Market With Nemluvio Approval
Mar 10 2025
• By Jessica Merrill
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
Dupixent Data Could Scratch A Regulatory Itch
Sep 13 2024
• By Elizabeth Cairns
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
Leo Shrugs Off Timber Drug Failure As Revenues Roar
Aug 27 2024
• By Kevin Grogan
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
Leo’s Congenital Ichthyosis Candidate Fails Phase III Study
Aug 21 2024
• By Joseph Haas
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.